Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS)

Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a028977. doi: 10.1101/cshperspect.a028977.

Abstract

Multiple sclerosis (MS) is a multifocal demyelinating disease of the central nervous system (CNS) leading to the progressive destruction of the myelin sheath surrounding axons. It can present with variable clinical and pathological manifestations, which might reflect the involvement of distinct pathogenic processes. Although the mechanisms leading to the development of the disease are not fully understood, numerous evidences indicate that MS is an autoimmune disease, the initiation and progression of which are dependent on an autoimmune response against myelin antigens. In addition, genetic susceptibility and environmental triggers likely contribute to the initiation of the disease. At this time, there is no cure for MS, but several disease-modifying therapies (DMTs) are available to control and slow down disease progression. A good number of these DMTs were identified and tested using animal models of MS referred to as experimental autoimmune encephalomyelitis (EAE). In this review, we will recapitulate the characteristics of EAE models and discuss how they help shed light on MS pathogenesis and help test new treatments for MS patients.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens / immunology
  • B-Lymphocytes / physiology
  • CD4-Positive T-Lymphocytes / physiology
  • CD8-Positive T-Lymphocytes / physiology
  • Encephalomyelitis, Autoimmune, Experimental / immunology
  • Encephalomyelitis, Autoimmune, Experimental / physiopathology*
  • Humans
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / physiopathology*
  • Myelin Basic Protein / physiology
  • Myelin Proteolipid Protein / physiology
  • Myelin-Oligodendrocyte Glycoprotein / physiology

Substances

  • Antigens
  • Myelin Basic Protein
  • Myelin Proteolipid Protein
  • Myelin-Oligodendrocyte Glycoprotein